Soledad Gomez Gonzalez
Investigador post-doc
Research group
The researcher has a degree in Biotechnology since 2011 and a master's degree in Administration and Management of Biotechnological Companies.
In 2013, she obtained the Master in Biochemistry, Molecular Biology and Biomedicine at the Autonomous University of Barcelona.
In 2017, she obtained the title of doctor. Thesis "Developmental tumors, epigenetics and miRNAs" at the University of Barcelona.
In 2011, she did a stay in the Laboratory of Virology and Molecular Genetics at Tufts University in Boston, under the direction of Dr. John Coffin. And in 2015 the Biomedical Epigenomics Laboratory of the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) in Barcelona carried out a stay, under the direction of Dr. José Ignacio Martín Subero.
Since 2020 she has been part of the Faculty of Doctors of the University of Barcelona.
She is currently working as a postdoctoral researcher in the Translational Genomics research group under the direction of Dr. Cinzia Lavarino (Principal Investigator) within the Developmental Tumors Laboratory, included in the IRSJD Pediatric Cancer Program. Her research line is focused on Bioinformatics and Big Data analysis for the identification of biomarkers and the development of classifiers that can be quickly transferred to clinical practice.
She currently leads the Design, Analysis and Interpretation of Data -OMICS (DAI-Omics) Unit of the Sant Joan de Déu Foundation, which provides service to research groups.
Professional network profiles
Last Publications
- Gomez-Gonzalez S, Llano-Viles J, Garcia-López M, Garrido- García A, Suñol M, Lemos I, Pérez-Jaume S, Salvador-Marcos N, Gene-Olaciregui N, Galán RA, Santa-María López V, Pérez-Somarriba M, Castañeda-Heredia A, Hinojosa J, Winter U, Moreira FB, Lubieniecki F, Vazquez V, Mora J, Cruz-Martínez O, Morales-La Madrid A, Perera A and Lavarino C EpiGe: A machine-learning strategy for rapid classification of medulloblastoma using PCR-based methyl-genotyping iScience . 26(9): 107598-107598.
- Fanlo, L, Gomez-Gonzalez S, Rozalen, C, Perez-Nunez, I, Sangrador, I, Tomas-Daza, L, Gautier, EL, Usieto, S, Rebollo, E, Vilà-Ubach M, Carcaboso AM, Javierre, BM, Celia-Terrassa, T, Lavarino C, Marti, E and Le Dreau, G Neural crest-related NXPH1/a-NRXN signaling opposes neuroblastoma malignancy by inhibiting organotropic metastasis Oncogene . 42(28): 2218-2233.
- Esperanza-Cebollada E, Gomez-Gonzalez S, Pérez-Jaume S, Vega-García N, Vicente-Garces C, Richarte M, Rives-Solà S, Català-Temprano A, Torrebadell-Burriel M and Camós-Guijosa M A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemia BRITISH JOURNAL OF HAEMATOLOGY . 202(1): 96-110.
Projects
- Project name:
- Multi-ómica y cribado masivo de fármacos para el tratamiento dirigido del Neuroblastoma resistente al tratamiento
- Leader
- Cinzia Emilia Lavarino , Marta García López
- Funding entities:
- Instituto de Salud Carlos III (ISCIII)
- Code
- PI23/00120
- Starting - finishing date:
- 2024 - 2026
- Project name:
- SGR 2022-2024_Grup de recerca en tumors del desenvolupament
- Leader
- Jaume Mora Graupera
- Funding entities:
- Agaur - Agència de Gestió d'Ajuts Universitaris i de Recerca
- Code
- 2021 SGR 01612
- Starting - finishing date:
- 2022 - 2025
- Project name:
- SEHOP-PENCIL study - Personalised mEdiciNe for Cancer in chILdren in Spain
- Leader
- Cinzia Emilia Lavarino
- Funding entities:
- Lavarino, Cinzia Emilia, Instituto de Salud Carlos III (ISCIII), Fundació Privada per a la Recerca i la Docència Sant Joan de Déu - FSJD
- Code
- PMP21/00075
- Starting - finishing date:
- 2022 - 2025
News
-
Automated learning app improves accessibility to medulloblastoma classification
A team from the Sant Joan de Déu Research Institute, Sant Joan de Déu Hospital, and the Polytechnic University of Catalonia, has developed an artificial intelligence-based application to make the classification of medulloblastoma subgroups more accessible, less costly, and faster
-
A nanomedicine to improve treatment of Ewing sarcoma
A team led by Dr. Ángel Montero Carcaboso at the Institut de Recerca Sant Joan de Déu (IRSJD) shows that albumin nanoparticles improve the biopharmaceutical properties of paclitaxel in a rare type of tumor called Ewing sarcoma. The publication is highlighted on today's cover of the Journal of Controlled Release.